AI-generated analysis. Always verify with the original filing.
Incannex Healthcare Inc. terminated a material definitive agreement previously amended on May 27, 2025, issued a press release on March 12, 2026 announcing its enhanced Phase 2 dose-optimisation study, and furnished a corporate presentation as Exhibit 99.1.
Event Type
Disclosure
Mandatory
Variant
8-K
. Termination of a Material Definitive Agreement As previously disclosed, on May 27, 2025, Incannex Healthcare Inc. (the “Company”) entered into an Amended and
, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
. Other Events On March 12, 2026, the Company issued a press release announcing its enhanced Phase 2 dose-optimisation study. A copy of the press release is att
. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation, dated March 12, 2026. 99.2 Press Release of Incannex Healt